CAS NO: | 120615-25-0 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | CKI-7 free base is a potent and ATP-competitivecasein kinase1 (CK1)inhibitor with anIC50of 6 μM and aKiof 8.5 μM. CKI-7 free base is a selectiveCdc7 kinaseinhibitor. CKI-7 free base also inhibitsSGK,ribosomal S6 kinase-1 (S6K1)andmitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect oncasein kinaseII and other protein kinases[1][2][3][4]. | ||||||||||||||||
IC50& Target[1][2][3] |
| ||||||||||||||||
体外研究 (In Vitro) | CKI-7 (0.1-10 μM; 5 days; ES cells) treatment significantly increases the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers nestin and βIII-tubulin, in a concentration-dependent manner[1]. RT-PCR[1]
Western Blot Analysis[1]
| ||||||||||||||||
体内研究 (In Vivo) | In vivo dose-dependent anti-tumor activity of CKI-7 is demonstrated in a SCID-Beige mouse systemic tumor model utilzing a recently isolated Philadelphia chromosome positive acute lymphoblastic leukemia cell line. Standard cell cycle synchronization studies established that exposure to CKI-7 results in cell cycle dependent caspase 3 activation and apoptotic cell death[2]. | ||||||||||||||||
分子量 | 285.75 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C11H12ClN3O2S | ||||||||||||||||
CAS 号 | 120615-25-0 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 25 mg/mL(87.49 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|